JP2007500715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500715A5 JP2007500715A5 JP2006522072A JP2006522072A JP2007500715A5 JP 2007500715 A5 JP2007500715 A5 JP 2007500715A5 JP 2006522072 A JP2006522072 A JP 2006522072A JP 2006522072 A JP2006522072 A JP 2006522072A JP 2007500715 A5 JP2007500715 A5 JP 2007500715A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- cycloalkyl
- group
- aralkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims 45
- 239000001257 hydrogen Substances 0.000 claims 45
- 125000003710 aryl alkyl group Chemical group 0.000 claims 33
- 125000000753 cycloalkyl group Chemical group 0.000 claims 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 29
- 125000003118 aryl group Chemical group 0.000 claims 29
- 125000001072 heteroaryl group Chemical group 0.000 claims 29
- 125000000623 heterocyclic group Chemical group 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 21
- 125000005843 halogen group Chemical group 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 21
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 18
- -1 chloro, methyl Chemical group 0.000 claims 18
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 150000002431 hydrogen Chemical class 0.000 claims 16
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 14
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 14
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 14
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims 14
- 229940079593 drug Drugs 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000003367 polycyclic group Chemical group 0.000 claims 6
- 230000005856 abnormality Effects 0.000 claims 5
- 108010087894 Fatty acid desaturases Proteins 0.000 claims 4
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims 2
- 101000631826 Homo sapiens Stearoyl-CoA desaturase Proteins 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 102000055981 human SCD1 Human genes 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 125000004385 trihaloalkyl group Chemical group 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- HZYJFYDBOVZGIW-UHFFFAOYSA-N [4-[6-(2-phenylethoxy)pyridazin-3-yl]piperazin-1-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2N=NC(OCCC=3C=CC=CC=3)=CC=2)CC1 HZYJFYDBOVZGIW-UHFFFAOYSA-N 0.000 claims 1
- WBLYCICMFISNEP-UHFFFAOYSA-N [4-[6-(2-phenylethylamino)pyridazin-3-yl]piperazin-1-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2N=NC(NCCC=3C=CC=CC=3)=CC=2)CC1 WBLYCICMFISNEP-UHFFFAOYSA-N 0.000 claims 1
- KIMDQFVNARRKRG-UHFFFAOYSA-N [4-[6-(2-phenylethylsulfanyl)pyridazin-3-yl]piperazin-1-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2N=NC(SCCC=3C=CC=CC=3)=CC=2)CC1 KIMDQFVNARRKRG-UHFFFAOYSA-N 0.000 claims 1
- KOTQLIKJTDTRGO-UHFFFAOYSA-N [4-[6-(2-phenylethylsulfinyl)pyridazin-3-yl]piperazin-1-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2N=NC(=CC=2)S(=O)CCC=2C=CC=CC=2)CC1 KOTQLIKJTDTRGO-UHFFFAOYSA-N 0.000 claims 1
- SLRFPPGXCUIOEE-UHFFFAOYSA-N [4-[6-(2-phenylethylsulfonyl)pyridazin-3-yl]piperazin-1-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)N1CCN(C=2N=NC(=CC=2)S(=O)(=O)CCC=2C=CC=CC=2)CC1 SLRFPPGXCUIOEE-UHFFFAOYSA-N 0.000 claims 1
- ACASVUBSIKGUOX-UHFFFAOYSA-N [4-[6-(3-methylbutylsulfanyl)pyridazin-3-yl]piperazin-1-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound N1=NC(SCCC(C)C)=CC=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 ACASVUBSIKGUOX-UHFFFAOYSA-N 0.000 claims 1
- XTRLGWKVRHBAFP-UHFFFAOYSA-N [4-[6-[methyl(2-phenylethyl)amino]pyridazin-3-yl]piperazin-1-yl]-[2-(trifluoromethyl)phenyl]methanone Chemical compound C=1C=C(N2CCN(CC2)C(=O)C=2C(=CC=CC=2)C(F)(F)F)N=NC=1N(C)CCC1=CC=CC=C1 XTRLGWKVRHBAFP-UHFFFAOYSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 1
- UPDYFVHFGPENGT-UHFFFAOYSA-N n-[6-[4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl]pyridazin-3-yl]propane-1-sulfonamide Chemical compound N1=NC(NS(=O)(=O)CCC)=CC=C1N1CCN(C(=O)C=2C(=CC=CC=2)C(F)(F)F)CC1 UPDYFVHFGPENGT-UHFFFAOYSA-N 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49111603P | 2003-07-30 | 2003-07-30 | |
| US49109503P | 2003-07-30 | 2003-07-30 | |
| US60/491,116 | 2003-07-30 | ||
| US60/491,095 | 2003-07-30 | ||
| PCT/US2004/024541 WO2005011653A2 (en) | 2003-07-30 | 2004-07-29 | Pyridazine derivatives and their use as therapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007500715A JP2007500715A (ja) | 2007-01-18 |
| JP2007500715A5 true JP2007500715A5 (https=) | 2007-09-13 |
| JP4831577B2 JP4831577B2 (ja) | 2011-12-07 |
Family
ID=34118852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522072A Expired - Fee Related JP4831577B2 (ja) | 2003-07-30 | 2004-07-29 | ピリダジン誘導体および治療剤としての用途 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7514436B2 (https=) |
| EP (2) | EP2316826A1 (https=) |
| JP (1) | JP4831577B2 (https=) |
| KR (1) | KR20060037410A (https=) |
| CN (1) | CN101712653A (https=) |
| AT (1) | ATE555789T1 (https=) |
| AU (1) | AU2004261249B2 (https=) |
| BR (1) | BRPI0412343A (https=) |
| CA (1) | CA2533897A1 (https=) |
| EC (1) | ECSP066315A (https=) |
| ES (1) | ES2386353T3 (https=) |
| IL (1) | IL173032A0 (https=) |
| MA (1) | MA28009A1 (https=) |
| NO (1) | NO20060974L (https=) |
| RU (1) | RU2006105716A (https=) |
| SG (1) | SG145699A1 (https=) |
| TN (1) | TNSN06032A1 (https=) |
| WO (1) | WO2005011653A2 (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517884B2 (en) | 1998-03-30 | 2009-04-14 | Kalypsys Inc. | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
| US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| SI1867644T1 (sl) * | 2003-07-24 | 2009-10-31 | Euro Celtique Sa | Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine |
| US7759348B2 (en) * | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| US7754711B2 (en) * | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| EP1648874B1 (en) * | 2003-07-30 | 2011-10-05 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| CN101712653A (zh) * | 2003-07-30 | 2010-05-26 | 泽农医药公司 | 哒嗪衍生物和它们作为治疗剂的用途 |
| EP2289510A1 (en) | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| CA2580762A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
| EP1807085B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
| AR051091A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
| CA2580857A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| AU2005286648A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| MX2007005205A (es) | 2004-10-29 | 2007-05-11 | Kalypsys Inc | Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma. |
| WO2006095822A1 (ja) * | 2005-03-11 | 2006-09-14 | Ono Pharmaceutical Co., Ltd. | スルホンアミド化合物およびその医薬 |
| WO2006125194A2 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
| WO2006125180A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
| WO2006125179A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
| AU2006343359A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| JP2009501733A (ja) * | 2005-07-20 | 2009-01-22 | メルク フロスト カナダ リミテツド | ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのヘテロ芳香族化合物 |
| EP1940815B1 (en) | 2005-10-25 | 2018-08-15 | Kalypsys, Inc. | Salts of modulators of ppar and methods of treating metabolic disorders |
| EP1966183A4 (en) * | 2005-12-20 | 2010-12-29 | Merck Frosst Canada Ltd | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A-DELTA-9-DESATURASE |
| WO2007136746A2 (en) * | 2006-05-19 | 2007-11-29 | Xenon Pharmaceuticals Inc. | Macrocyclic compounds and their uses as stearoyl-coa desaturase |
| WO2007143597A2 (en) | 2006-06-05 | 2007-12-13 | Novartis Ag | Organic compounds |
| EP2032566A4 (en) * | 2006-06-12 | 2009-07-08 | Merck Frosst Canada Ltd | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE |
| JP2010501567A (ja) | 2006-08-24 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物 |
| US20080182851A1 (en) * | 2006-11-20 | 2008-07-31 | Glenmark Pharmaceuticals S.A. | Acetylene derivatives as stearoyl coa desaturase inhibitors |
| TW200826936A (en) | 2006-12-01 | 2008-07-01 | Merck Frosst Canada Ltd | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| US20080194557A1 (en) * | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
| US20080200458A1 (en) * | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
| WO2008091863A1 (en) | 2007-01-23 | 2008-07-31 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| AR064965A1 (es) | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
| WO2008096746A1 (ja) | 2007-02-06 | 2008-08-14 | Takeda Pharmaceutical Company Limited | スピロ化合物およびその用途 |
| DE102007007751A1 (de) * | 2007-02-16 | 2008-08-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20090188A1 (es) | 2007-03-15 | 2009-03-20 | Novartis Ag | Compuestos heterociclicos como moduladores de la senda de hedgehog |
| DK2142529T3 (da) * | 2007-04-27 | 2014-02-10 | Purdue Pharma Lp | Trpv1-antagonister og anvendelser deraf |
| US7842696B2 (en) | 2007-06-21 | 2010-11-30 | Forest Laboratories Holdings Limited | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase |
| DE102007035333A1 (de) * | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2009037542A2 (en) | 2007-09-20 | 2009-03-26 | Glenmark Pharmaceuticals, S.A. | Spirocyclic compounds as stearoyl coa desaturase inhibitors |
| GB0722077D0 (en) | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| WO2010028761A1 (de) * | 2008-09-09 | 2010-03-18 | Sanofi-Aventis | 2-heteroaryl-pyrrolo[3, 4-c]pyrrol-derivate und ihre verwendung als scd inhibitoren |
| WO2010071610A1 (en) | 2008-12-19 | 2010-06-24 | Agency For Science, Technology And Research (A*Star) | Severe chikungunya biomarkers |
| WO2010075356A1 (en) * | 2008-12-23 | 2010-07-01 | Forest Laboratories Holdings Limited | Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
| CA2750564A1 (en) | 2009-02-17 | 2010-08-26 | Merck Canada Inc. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| GB0907425D0 (en) * | 2009-04-29 | 2009-06-10 | Glaxo Group Ltd | Compounds |
| EP2459568A4 (en) | 2009-07-28 | 2013-02-27 | Merck Frosst Canada Ltd | NEW SPIRO COMPOUNDS AS AN INHIBITORS OF STEAROYL COENZYME A DELTA 9 DESATURASE |
| FR2948939B1 (fr) * | 2009-08-05 | 2013-03-22 | Pf Medicament | Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine |
| HRP20170507T1 (hr) | 2011-06-22 | 2017-06-02 | Purdue Pharma Lp | Trpv1 antagonisti uključujući dihidroksi supstituente i njihove uporabe |
| WO2013134546A1 (en) | 2012-03-07 | 2013-09-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| BR112014029365A2 (pt) | 2012-05-22 | 2017-06-27 | Hoffmann La Roche | inibidores seletivos de células indiferenciadas |
| WO2016022955A1 (en) | 2014-08-07 | 2016-02-11 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| CA2977817A1 (en) * | 2015-03-04 | 2016-09-09 | Children's Hospital Medical Center | Methods for treating cancer |
| AU2017281907B2 (en) | 2016-06-23 | 2021-10-21 | St. Jude Children's Research Hospital, Inc. | Small molecule modulators of pantothenate kinases |
| US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| EA201991650A1 (ru) | 2017-01-06 | 2020-01-20 | Юманити Терапьютикс, Инк. | Способы лечения неврологических расстройств |
| ES2747768T3 (es) | 2017-03-20 | 2020-03-11 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| KR102728619B1 (ko) | 2017-12-27 | 2024-11-08 | 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 | 판토테네이트 키나제의 소분자 조절제 |
| EP3731859B1 (en) | 2017-12-27 | 2025-08-20 | St. Jude Children's Research Hospital, Inc. | Pyridazine compounds for use to treat disorders associated with castor |
| CN111868055B (zh) * | 2018-02-16 | 2024-03-08 | 勃林格殷格翰国际有限公司 | Trpc6的抑制剂 |
| BR112020019191A2 (pt) | 2018-03-23 | 2021-01-05 | Yumanity Therapeutics, Inc. | Compostos e seus usos |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| US20220378756A1 (en) | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| CA3188340A1 (en) | 2020-08-13 | 2022-02-17 | Boehringer Ingelheim International Gmbh | Treatment of cognitive impairement associated with schizophrenia |
| CA3195702A1 (en) | 2020-10-13 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Process of reworking |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2985657A (en) * | 1959-10-12 | 1961-05-23 | Paul A J Janssen | 1-(aroylalkyl)-4-heterocyclylpiperazines |
| ATE3294T1 (de) | 1978-10-02 | 1983-05-15 | Gruppo Lepetit S.P.A. | 6-aminosubstituierte n-pyrrolyl-3-pyridazinamine, deren herstellung und sie enthaltende pharmazeutische antihypertensive zusammensetzungen. |
| ZM1785A1 (en) * | 1984-03-26 | 1986-03-27 | Janssen Pharmaceutica Nv | Anti-virally active phyridazinamines |
| US5001125A (en) * | 1984-03-26 | 1991-03-19 | Janssen Pharmaceutica N.V. | Anti-virally active pyridazinamines |
| ES8802151A1 (es) * | 1985-07-31 | 1988-04-01 | Janssen Pharmaceutica Nv | Un procedimiento para la preparacion de nuevos piridazinaminas. |
| US5106973A (en) * | 1987-11-23 | 1992-04-21 | Janssen Pharmaceutica N.V. | Pyridzainamine derivatives |
| MY104343A (en) * | 1987-11-23 | 1994-03-31 | Janssen Pharmaceutica Nv | Novel pyridizinamine deravatives |
| US5166147A (en) * | 1990-07-09 | 1992-11-24 | The Du Pont Merck Pharmaceutical Company | 4-heteroaryl-and 4-aryl-1,4-dihydropyridine, derivatives with calcium agonist and alpha1 -antagonist activity |
| DE19614204A1 (de) * | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| JPH107572A (ja) * | 1996-06-17 | 1998-01-13 | Sumitomo Pharmaceut Co Ltd | 腫瘍壊死因子産生阻害剤 |
| US5976497A (en) * | 1997-08-04 | 1999-11-02 | Resolution Pharmaceuticals, Inc. | Dopamine D4 receptor ligands |
| AU8096798A (en) * | 1997-06-27 | 1999-01-19 | Resolution Pharmaceuticals Inc. | Dopamine d4 receptor ligands |
| EP1315831B8 (en) | 2000-02-24 | 2010-09-01 | Xenon Pharmaceuticals Inc. | Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| US7160878B2 (en) * | 2000-07-27 | 2007-01-09 | Eli Lilly And Company | Substituted heterocyclic amides |
| US7232662B2 (en) | 2000-09-26 | 2007-06-19 | Xenon Pharmaceuticals Inc. | Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5 |
| KR20040010713A (ko) | 2001-06-15 | 2004-01-31 | 야마노우치세이야쿠 가부시키가이샤 | 페닐피리딘 카보닐 피페라진 유도체 |
| JP4186518B2 (ja) * | 2001-06-15 | 2008-11-26 | アステラス製薬株式会社 | フェニルピリジン誘導体 |
| AU2003203148A1 (en) * | 2002-02-05 | 2003-09-02 | High Point Pharmaceuticals, Llc | Novel aryl- and heteroarylpiperazines |
| ES2306859T3 (es) * | 2002-03-13 | 2008-11-16 | Janssen Pharmaceutica Nv | Derivados de sulfonil como nuevos inhibidores de histona deacetilasa. |
| OA12793A (en) | 2002-03-13 | 2006-07-10 | Janssen Pharmaceutica Nv | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase. |
| DE60326436D1 (en) * | 2002-03-13 | 2009-04-16 | Janssen Pharmaceutica Nv | Aminoderivate als histone-deacetylase-inhibitoren |
| MXPA04010555A (es) * | 2002-04-25 | 2005-02-17 | Pharmacia Corp | Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa. |
| US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| JP2004203871A (ja) * | 2002-12-13 | 2004-07-22 | Yamanouchi Pharmaceut Co Ltd | 医薬組成物 |
| GB0303439D0 (en) * | 2003-02-14 | 2003-03-19 | Pfizer Ltd | Antiparasitic terpene alkaloids |
| EP1648874B1 (en) * | 2003-07-30 | 2011-10-05 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| CN101712653A (zh) * | 2003-07-30 | 2010-05-26 | 泽农医药公司 | 哒嗪衍生物和它们作为治疗剂的用途 |
| US20050119252A1 (en) * | 2003-10-22 | 2005-06-02 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| TW200538433A (en) * | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| EP1781293A1 (en) * | 2004-06-04 | 2007-05-09 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
-
2004
- 2004-07-29 CN CN200910224929A patent/CN101712653A/zh active Pending
- 2004-07-29 JP JP2006522072A patent/JP4831577B2/ja not_active Expired - Fee Related
- 2004-07-29 EP EP10184440A patent/EP2316826A1/en not_active Withdrawn
- 2004-07-29 EP EP04779555A patent/EP1651616B1/en not_active Expired - Lifetime
- 2004-07-29 US US10/566,856 patent/US7514436B2/en not_active Expired - Fee Related
- 2004-07-29 WO PCT/US2004/024541 patent/WO2005011653A2/en not_active Ceased
- 2004-07-29 RU RU2006105716/04A patent/RU2006105716A/ru not_active Application Discontinuation
- 2004-07-29 CA CA002533897A patent/CA2533897A1/en not_active Abandoned
- 2004-07-29 BR BRPI0412343-3A patent/BRPI0412343A/pt not_active IP Right Cessation
- 2004-07-29 ES ES04779555T patent/ES2386353T3/es not_active Expired - Lifetime
- 2004-07-29 AU AU2004261249A patent/AU2004261249B2/en not_active Ceased
- 2004-07-29 AT AT04779555T patent/ATE555789T1/de active
- 2004-07-29 KR KR1020067002006A patent/KR20060037410A/ko not_active Ceased
- 2004-07-29 SG SG200805678-0A patent/SG145699A1/en unknown
-
2006
- 2006-01-09 IL IL173032A patent/IL173032A0/en unknown
- 2006-01-25 EC EC2006006315A patent/ECSP066315A/es unknown
- 2006-01-27 TN TNP2006000032A patent/TNSN06032A1/en unknown
- 2006-02-27 MA MA28837A patent/MA28009A1/fr unknown
- 2006-02-28 NO NO20060974A patent/NO20060974L/no not_active Application Discontinuation
-
2009
- 2009-02-20 US US12/390,117 patent/US8148378B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007500715A5 (https=) | ||
| JP2008513504A5 (https=) | ||
| JP2007500716A5 (https=) | ||
| JP3600832B2 (ja) | 新規１，２，４−トリアゾール系化合物 | |
| JP2007500719A5 (https=) | ||
| JP4958786B2 (ja) | 複素環誘導体および治療薬としてのそれらの使用 | |
| JP2008513498A5 (https=) | ||
| RU2006105716A (ru) | Производные пиридазина и их применение в качестве терапевтических средств | |
| JP2008513515A5 (https=) | ||
| JP6409004B2 (ja) | ソルチリン阻害剤としてのｎ置換された５置換フタルアミド酸 | |
| JP2011523945A5 (https=) | ||
| JP2008513516A5 (https=) | ||
| SG192439A1 (en) | Organic compounds | |
| JP2008513514A5 (https=) | ||
| JP2000309579A (ja) | 新規アミノトリアゾール化合物、これらの製造方法及びこれらを含む医薬組成物 | |
| JP7710215B2 (ja) | ピロール化合物 | |
| JP2007500720A5 (https=) | ||
| AU2018202148A1 (en) | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | |
| JP2009533410A5 (https=) | ||
| MX2007009593A (es) | Derivados de piridazina y su uso como agentes terapeuticos. | |
| AU2008263166A1 (en) | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | |
| TW200815420A (en) | Organic compounds | |
| JP2005508923A5 (https=) | ||
| JP2018506571A (ja) | Ｒｈｏ関連プロテインキナーゼの阻害及び疾患の治療のためのインダゾリルチアジアゾールアミン及び関連する化合物 | |
| EP3675858B1 (en) | Imidazo[1,5-a]pyrazine compounds and compositions for ire1 inhibition |